Wintermute is Now Recruiting Patients for the ZosterEase Phase Ib Clinical Trial. Read more .

Wintermute Joins AMR Hub to Combat Antimicrobial Resistance

Wintermute Biomedical partners with the AMR Hub to advance the fight against antimicrobial resistance.

Wintermute Biomedical
May 22, 2024

Wintermute Biomedical is proud to announce its partnership with the ARC Research Hub to Combat Antimicrobial Resistance (AMR Hub), a world-first partnership that brings together industry, researchers, and end users to tackle the pressing global issue of antimicrobial resistance (AMR). This partnership supports our ongoing collaboration with the University of Melbourne led by A/Prof Fabian Kong and in partnership with A/Prof Antonio Celentano at the Melbourne Dental School, to address the challenge of antimicrobial-resistant oral gonorrhoea.

The AMR Hub is a pioneering initiative designed to transform the landscape of antimicrobial resistance and stewardship through a highly integrated approach. By fostering a pre-commercialisation environment, the Hub aims to bridge the gap between social and laboratory-based preclinical challenges, providing comprehensive diagnostic, pharmaceutical, and end-user solutions. The ARC Hub is committed to addressing the global challenge of AMR in Australia through innovative partnerships that span industry, research, and end-user sectors.

The goals of the Hub include developing new molecular diagnostic technologies, enhancing processes for identifying potential antibiotic compounds, and advising on antimicrobial stewardship to improve health outcomes globally. The Hub's research themes focus on creating real-time diagnostic tools to determine AMR status, enhancing treatments for sexually transmitted infections, developing tools to detect active bacterial infections, and promoting innovation in AMR through multisectoral collaboration.

Joining the AMR Hub significantly raises Wintermute's profile in the AMR community and strengthens our connections with world-renowned researchers and stakeholders. This collaboration not only underscores our commitment to combating antimicrobial resistance but also positions us at the forefront of cutting-edge research and innovation. In collaboration with A/Prof Fabian Kong at the University of Melbourne, Wintermute is focused on tackling antimicrobial resistant oral gonorrhoea. This partnership leverages the unique strengths of both institutions to drive forward research and develop effective treatments for this challenging infection.

Wintermute's involvement in the AMR Hub aligns with our mission to innovate and contribute to global health solutions. By becoming a Partner Investigator in this transformative initiative, we are poised to make significant strides in the fight against antimicrobial resistance, ensuring better health outcomes for future generations. Wintermute Biomedical is excited to be part of this groundbreaking effort and looks forward to the collaborative advancements that will emerge from this partnership.

For more information about our work and the AMR Hub, please contact us or visit the AMR Hub on Twitter and LinkedIn.